Dialog Box

Rare Cancers Australia

Ep 2: Carlo Montagner

Carlo Montagner

Co-Founder and CEO, Specialised Therapeutics Australia
Risks and rewards: getting new medications into the hands of patients

In this episode, RCA Chief Executive Richard Vines speaks to Carlo Montagner about:

  • His move from psychology to pharma
  • Building a strong foundation in the industry
  • Founding STA with his wife
  • The barriers to, and costs of, supplying drugs in Australia
  • How the process can be improved and simplified
  • Accessing drugs not listed on the PBS
  • The responsibility of clinicians around reimbursement
  • The challenges and opportunities of Health Technology Assessment (HTA)
  • Why STA is expanding into Asia
  • His family’s personal experience with rare cancer
  • Why he is passionate about bringing rare cancer drugs to Australia
  • His vision for the future
Listen to the episode as a podcast

Read Episode Transcript 

More about Carlo Montagner

Specialised Therapeutics Australia (STA) is a pharmaceutical company that has been instrumental in helping Australians living with rare cancer to access new medications that would otherwise be out of reach. Before co-founding STA, Carlo held senior roles at some of the world’s largest pharmaceutical companies.

More about Richard Vines

Richard is the co-Founder and Chief Executive of Rare Cancers Australia. He is Convener and Co-chair of the National Oncology Alliance, and Deputy Chair of Omico. Richard also serves as an associate investigator on several research projects and is a spokesperson for cancer patient advocacy issues in both Australia and the Asia Pacific region.

Next Episode

Our responsibility to patients who can’t afford to wait

John was Director of Cancer Medicine at the Peter MacCallum Cancer Centre for 17 years, as well as their Chief Medical Officer for six.

He is highly regarded both nationally and internationally as a leader in his field, is a mentor to some of the most accomplished clinicians in Australia, and is a well-known advocate for patient access to new cancer drugs.

Learn more